Company intelligence / Profile preview

Shanghai Bio-heart Biological Technology

Shanghai, Shanghai, Chinabio-heart.com ↗

Ownership: Private
Employees: ~63
Development stage: Other

Overview

Shanghai Bio-heart has completed feasibility and confirmatory clinical trials for its core products—the second-generation bioresorbable scaffold system ("Bioheart®") for coronary artery disease and the multi-electrode renal denervation system ("Iberis® 2nd") for hypertension. Both have completed patient follow-up in pivotal studies in China, with additional trials ongoing or planned in Japan. The sirolimus drug-eluting balloon catheter is expected to reach later-stage development by 2026. No commercial approvals yet as of mid–2025.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

TerumoXinzhi Medical

Beyond the preview

Go deeper on Shanghai Bio-heart Biological Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Bio-heart Biological Technology.

Explore the full profile